温かい自己免疫性溶血性貧血(WAIHA)治療薬の世界市場:疫学予測

◆英語タイトル:Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030
◆商品コード:DELV20JU228
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(228名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Warm Autoimmune Hemolytic Anemia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017–2030

Warm Autoimmune Hemolytic Anemia Disease Understanding
Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation. W-AIHA is the most common type of autoimmune hemolytic anemia, comprising ∼70-80% of all adult cases and ∼50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology. In contrast, the rest is secondary to recognizable underlying disorders, such as lymphoproliferative syndromes—malignant diseases, including chronic lymphoblastic leukemia (CLL), non-Hodgkin’s lymphoma, and solid tumors.

Warm Autoimmune Hemolytic Anemia Epidemiology
The Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Warm Autoimmune Hemolytic Anemia are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA) scenario of Warm Autoimmune Hemolytic Anemia (WAIHA)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period,along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Warm Autoimmune Hemolytic Anemia (WAIHA) in 7 MM was found to be 82,045, in the year 2017.

Report Scope
• The report covers detailed overview of Warm Autoimmune Hemolytic Anemia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• The report provides the insight about the historical and forecasted patient pool of Warm Autoimmune Hemolytic Anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan

• The Report assesses the disease risk and burden and highlights the unmet needs of the disease

• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population

• The report provides the segmentation of the disease epidemiology by Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA in 7MM

Key strengths
• 11 Year Forecast of Warm Autoimmune Hemolytic Anemia epidemiology

• 7MM Coverage

• Total prevalent cases of WAIHA

• Prevalent Cases according to segmentation: Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA

Key assessments
• Patient Segmentation

• Disease Risk & Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

【レポートの目次】

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 wAIHA Market Overview at a Glance

4.1 Market Share (%) Distribution of wAIHA in 2017

4.2 Market Share (%) Distribution of wAIHA in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Types

5.3 Causes

5.4 Signs and Symptoms

5.5 Pathophysiology

5.6 Manifestations

5.7 Diagnosis Immunohematological assessment of patients with AIHA DAT-negative AIHA

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 KOL Views

6.3 7MM Total Prevalent Patient Population of wAIHA

6.4 Assumptions and Rationale: 7MM

7 Country Wise-Epidemiology of wAIHA

7.1 The United States

7.1.1 Total Prevalent Cases of AIHA in the United States

7.1.2 Diagnosed Prevalence of wAIHA in the United States

7.1.3 Type-specific Prevalence of wAIHA in the United States

7.1.4 Gender-specific Prevalence of wAIHA in the United States

7.2 EU5

7.2.1 Germany

7.2.1.1 Total Prevalent Cases of AIHA in Germany

7.2.1.2 Diagnosed Prevalence of wAIHA in Germany

7.2.1.3 Type-specific Prevalence of wAIHA in Germany

7.2.1.4 Gender-specific Prevalence of wAIHA in Germany

7.2.2 France

7.2.2.1 Total Prevalent Cases of AIHA in France

7.2.2.2 Diagnosed Prevalence of wAIHA in France

7.2.2.3 Type-specific Prevalence of wAIHA in France

7.2.2.4 Gender-specific Prevalence of wAIHA in France

7.2.3 Italy

7.2.3.1 Total Prevalent Cases of AIHA in Italy

7.2.3.2 Diagnosed Prevalence of wAIHA in Italy

7.2.3.3 Type-specific Prevalence of wAIHA in Italy

7.2.3.4 Gender-specific Prevalence of wAIHA in Italy

7.2.4 Spain

7.2.4.1 Total Prevalent Cases of AIHA in Spain

7.2.4.2 Diagnosed Prevalence of wAIHA in Spain

7.2.4.3 Type-specific Prevalence of wAIHA in Spain

7.2.4.4 Gender-specific Prevalence of wAIHA in Spain

7.2.5 The United Kingdom

7.2.5.1 Total Prevalent Cases of AIHA in the UK

7.2.5.2 Diagnosed Prevalence of wAIHA in the UK

7.2.5.3 Type-specific Prevalence of wAIHA in the UK

7.2.5.4 Gender-specific Prevalence of wAIHA in the UK

7.3 Japan

7.3.1 Total Prevalent Cases of AIHA in Japan

7.3.2 Diagnosed Prevalence of wAIHA in Japan

7.3.3 Type-specific Prevalence of wAIHA in Japan

7.3.4 Gender-specific Prevalence of wAIHA in Japan

8 Treatment and Management of wAIHA

8.1 Sequential approach to treatment options for w-AIHA and common dosing regimens

8.1.1 First-line therapy

8.1.1.1 Corticosteroids

8.1.2 Second-line therapy

8.1.2.1 Splenectomy

8.1.2.2 Rituximab

8.1.2.3 Immunosuppressive drugs

8.1.2.4 Other Options

8.2 British Guidelines for WAIHA treatment

9 Case Study

10 Patient Journey

11 Unmet Needs

12 Appendix

12.1 Report Methodology

13 DelveInsight Capabilities

14 Disclaimer

15 About DelveInsight

Table 1: Classification of w-AIHA

Table 2: Prevalent Patient Population of wAIHA in 7MM (2017-2030)

Table 3: Total Prevalent Cases of AIHA in the United States (2017-2030)

Table 4: Diagnosed Prevalence of wAIHA in the United States (2017-2030)

Table 5: Type-specific Prevalence of wAIHA in the United States (2017-2030)

Table 6: Gender-specific Prevalence of wAIHA in the United States (2017-2030)

Table 7: Total Prevalent Cases of AIHA in Germany (2017-2030)

Table 8: Diagnosed Prevalence of wAIHA in Germany (2017-2030)

Table 9: Type-specific Prevalence of wAIHA in Germany (2017-2030)

Table 10: Gender-specific Prevalence of wAIHA in Germany (2017-2030)

Table 11: Total Prevalent Cases of AIHA in France (2017-2030)

Table 12: Diagnosed Prevalence of wAIHA in France (2017-2030)

Table 13: Type-specific Prevalence of wAIHA in France (2017-2030)

Table 14: Gender-specific Prevalence of wAIHA in France (2017-2030)

Table 15: Total Prevalent Cases of AIHA in Italy (2017-2030)

Table 16: Diagnosed Prevalence of wAIHA in Italy (2017-2030)

Table 17: Type-specific Prevalence of wAIHA in Italy (2017-2030)

Table 18: Gender-specific Prevalence of wAIHA in Italy (2017-2030)

Table 19: Total Prevalent Cases of AIHA in Spain (2017-2030)

Table 20: Diagnosed Prevalence of wAIHA in Spain (2017-2030)

Table 21: Type-specific Prevalence of wAIHA in Spain (2017-2030)

Table 22: Gender-specific Prevalence of wAIHA in Spain (2017-2030)

Table 23: Total Prevalent Cases of AIHA in the United Kingdom (2017-2030)

Table 24: Diagnosed Prevalence of wAIHA in the United Kingdom (2017-2030)

Table 25: Type-specific Prevalence of wAIHA in the United Kingdom (2017-2030)

Table 26: Gender-specific Prevalence of wAIHA in the United Kingdom (2017-2030)

Table 27: Total Prevalent Cases of AIHA in Japan (2017-2030)

Table 28: Diagnosed Prevalence of wAIHA in Japan (2017-2030)

Table 29: Type-specific Prevalence of wAIHA in Japan (2017-2030)

Table 30: Gender-specific Prevalence of wAIHA in Japan (2017-2030)

Table 31: Treatment Flow

Figure 1: SWOT Analysis of WAIHA

Figure 2 : Mechanisms of hemolysis in warm antibody autoimmune hemolytic anemia

Figure 3: Clinical-serologic associations with the direct Coombs test

Figure 4: Prevalent Patient Population of wAIHA in 7MM (2017-2030)

Figure 5: Total Prevalent Cases of AIHA in the United States (2017-2030)

Figure 6: Diagnosed Prevalence of wAIHA in the United States (2017-2030)

Figure 7: Type-specific Prevalence of wAIHA in the United States (2017-2030)

Figure 8: Gender-specific Prevalence of wAIHA in the United States (2017-2030)

Figure 9: Total Prevalent Cases of AIHA in Germany (2017-2030)

Figure 10: Diagnosed Prevalence of wAIHA in Germany (2017-2030)

Figure 11: Type-specific Prevalence of wAIHA in Germany (2017-2030)

Figure 12: Gender-specific Prevalence of wAIHA in Germany (2017-2030)

Figure 13: Total Prevalent Cases of AIHA in France (2017-2030)

Figure 14:Diagnosed Prevalence of wAIHA in France (2017-2030)

Figure 15: Type-specific Prevalence of wAIHA in France (2017-2030)

Figure 16: Gender-specific Prevalence of wAIHA in France (2017-2030)

Figure 17: Total Prevalent Cases of AIHA in Italy (2017-2030)

Figure 18: Diagnosed Prevalence of wAIHA in Italy (2017-2030)

Figure 19: Type-specific Prevalence of wAIHA in Italy (2017-2030)

Figure 20: Gender-specific Prevalence of wAIHA in Italy (2017-2030)

Figure 21: Total Prevalent Cases of AIHA in Spain (2017-2030)

Figure 22: Diagnosed Prevalence of wAIHA in Spain (2017-2030)

Figure 23: Type-specific Prevalence of wAIHA in Spain (2017-2030)

Figure 24: Gender-specific Prevalence of wAIHA in Spain (2017-2030)

Figure 25: Total Prevalent Cases of AIHA in the UK (2017-2030)

Figure 26: Diagnosed Prevalence of wAIHA in the UK (2017-2030)

Figure 27: Type-specific Prevalence of wAIHA in the UK (2017-2030)

Figure 28: Gender-specific Prevalence of wAIHA in the UK (2017-2030)

Figure 29: Total Prevalent Cases of AIHA in Japan (2017-2030)

Figure 30: Diagnosed Prevalence of wAIHA in Japan (2017-2030)

Figure 31: Type-specific Prevalence of wAIHA in Japan (2017-2030)

Figure 32: Gender-specific Prevalence of wAIHA in Japan (2017-2030)

Figure 33: Treatment algorithm for warm AIHA in adults

Figure 34: Mechanisms of hemolysis in warm antibody autoimmune hemolytic anemia

Figure 35: Unmet Needs of wAIHA

Figure 51: Market Drivers

Figure 52: Market Barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[温かい自己免疫性溶血性貧血(WAIHA)治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆